Log in
OTCMKTS:CYDY

CytoDyn Stock Forecast, Price & News

$3.37
+0.01 (+0.30 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$3.30
Now: $3.37
$3.41
50-Day Range
$3.00
MA: $3.86
$4.92
52-Week Range
$0.26
Now: $3.37
$10.01
Volume1.19 million shs
Average Volume6.25 million shs
Market Capitalization$1.92 billion
P/E RatioN/A
Dividend YieldN/A
Beta-1.08
CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. The company has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. CytoDyn Inc. is based in Vancouver, Washington.
Read More
CytoDyn logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.90 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYDY
Previous SymbolNASDAQ:CYDY
CUSIP23283M101
Phone360-980-8524

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-124,400,000.00

Miscellaneous

Employees6
Market Cap$1.92 billion
Next Earnings DateN/A
OptionableNot Optionable
$3.37
+0.01 (+0.30 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

How has CytoDyn's stock been impacted by Coronavirus?

CytoDyn's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYDY stock has increased by 227.2% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of CytoDyn?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for CytoDyn
.

How were CytoDyn's earnings last quarter?

CytoDyn Inc (OTCMKTS:CYDY) issued its quarterly earnings results on Tuesday, October, 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.01.
View CytoDyn's earnings history
.

What price target have analysts set for CYDY?

1 brokerages have issued 12-month price targets for CytoDyn's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate CytoDyn's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price.
View analysts' price targets for CytoDyn
.

Are investors shorting CytoDyn?

CytoDyn saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 23,659,300 shares, a decrease of 10.8% from the August 31st total of 26,536,800 shares. Based on an average daily volume of 7,273,400 shares, the short-interest ratio is currently 3.3 days.
View CytoDyn's Short Interest
.

Who are some of CytoDyn's key competitors?

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Gilead Sciences (GILD), Vaxart (VXRT), Nokia Oyj (NOK), Johnson & Johnson (JNJ), Pfizer (PFE), Moderna (MRNA) and Sorrento Therapeutics (SRNE).

Who are CytoDyn's key executives?

CytoDyn's management team includes the following people:
  • Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 56)
  • Mr. Michael D. Mulholland, CFO, Treasurer & Corp. Sec. (Age 67)
  • Dr. Denis R. Burger, Scientific Consultant (Age 75)
  • Dr. Richard G. Pestell M.B.A., M.D., MBA. M.D., Ph.D., Vice Chairman & Chief Medical Officer
  • Dr. Nitya G. Ray, Chief Technology Officer & Head of Process Sciences, Manufacturing and Supply Chain (Age 66)

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $3.37.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $1.92 billion. The biotechnology company earns $-124,400,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. CytoDyn employs 6 workers across the globe.

What is CytoDyn's official website?

The official website for CytoDyn is www.cytodyn.com.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.